Aviragen Therapeutics (AVIR) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Benchmark Reiterates Buy Rating on Cal-Maine Foods (CALM) as Q4 Estimates Trimmed
- Liberty Global (LBTYA) Reiterated at Buy by Benchmark Ahead of Q2 Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
